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Japonica Rhizome, SKI3246 on Gastrointestinal 
Motility in Guinea Pigs
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Background/Aims
There are limited therapeutic options available for irritable bowel syndrome with diarrhea (IBS-D). We tested the effects of 
Atractylodes japonica  rhizome, a perennial plant native to North Asia, on both upper and lower gastrointestinal (GI) motility 
in guinea pigs.
Methods
The extract of A. japonica rhizome was administered orally at different doses to test its effects on upper GI motility as determined 
from charcoal transit in native guinea pigs and in guinea pigs pretreated with thyrotropin-releasing hormone or mustard oil. 
Regarding its effect on lower GI motility, the removed guinea pig colon was suspended in a chamber containing Krebs-Henseleit 
solution and the transit time of artificial feces was measured with various dilutions of the extract. As for in vivo assay, weight 
and number of fecal pellets expelled were determined under the same drug preparation used in upper GI motility experiment.
Results
The extract of A. japonica rhizome had no significant effect on upper GI motility in either normal or altered physiological 
states. However, the extract increased colonic transit time in the in vitro model. In the fecal expulsion study, the cumulative 
weight and number of pellets did not differ significantly between the control group and groups treated with the extracts. In  
the animals pretreated in vivo with thyrotropin-releasing hormone, however, the weight and number of fecal pellets were sig-
nificantly decreased in animals treated with 300 mg/kg and 600 mg/kg doses of extract. 
Conclusions
Our findings suggest that the extract of A. japonica rhizome can be a potential agent for IBS-D.
(J Neurogastroenterol Motil 2015;21:352-360)
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Introduction
Atractylodes japonica, a perennial plant native to North Asia, 
has commonly been used as a remedy for digestive disorders, par-
ticularly diarrhea. In preliminary animal experiments, an extract 
of A. japonica rhizome (SKI3246) significantly reduced visceral 
pain in visceral hypersensitivity rats model using trinitrobenzene 
sulfonic acid (TNBS) or acetic acid.1 The treatment also amelio-
rated castor oil-induced diarrhea in mice (unpublished data). 
These findings suggest that SKI3246 may potentially provide 
some relief for irritable bowel syndrome (IBS), especially when 
diarrhea is a principal component. To further explore this possi-
bility, we assessed the effects of an A. japonica rhizome extract on 




Adult male Hartley guinea pigs (250-350 g; Orient Bio, Inc, 
Seoul, Korea) were acclimated to their holding room (tempera-
ture controlled at 21 ± 1oC, 50 ± 10% humidity and 12-hour 
light/dark cycle). A standard guinea pig diet (7006; Teklad 
Guinea Pig Diet, Harlan Laboratories, Madison, WI, USA) 
and drinking water were provided ad libitum. Guinea pigs were 
deprived of food overnight before the experiment, but were al-
lowed free access to water. Five to seven guinea pigs were used in 
each experimental group. All experiments were conducted in ac-
cordance with the Guide for the Care and Use of Laboratory 
Animals provided by the Animal Laboratory Ethics Committees 
of the Department of Laboratory Animal Medicine, Medical 
Research Center, Yonsei University College of Medicine.
Drugs and Chemicals
The following drugs and chemicals were used: charcoal 
(Sigma, St. Louis, MO, USA), mustard oil (MO) (Sigma), thy-
rotropin-releasing hormone (TRH) (Sigma), and extract of A. 
japonica rhizome, designated as SKI3246, from a pharmaceutical 
company (SKC, Seoul, Korea).1 Charcoal, MO, and SKI3246 
were administrated orally with charcoal as the binding agent. The 
TRH was mixed in saline and injected subcutaneously at a total 
dose of 100 g. Doses of drugs and chemicals used were based on 
the results of preliminary experiments as well as on previously 
published data.2,3
Experimental Design
Effect of SKI3246 on colonic transit time 
Guinea pigs were killed by a blow to the occipital region of 
the head and severing the carotid arteries. A 10-cm segment of 
colon was removed and the lumen was flushed clean with 
Krebs-Henseleit (K-H) solution (pH 7.4; 118 mM NaCl, 4.8 
mM KCl, 2.5 mM CaCl2, 1.2 mM KH2PO4, 1.5 mM MgSO4, 
25 mM NaHCO3, 11 mM glucose). The colonic preparations 
were set up immediately as described below and allowed to equili-
brate for at least 60 minutes before experiments began. The prep-
aration was secured horizontally in a peristaltic bath containing 
K-H solution, which was maintained at 37oC in 95% O2 and 5% 
CO2. Oral and anal ends of the colonic preparation were cannu-
lated to the inflow and outflow tubes, respectively.4,5
After the artificial feces (pellet) (12 mm × 4 mm) was in-
serted at the oral side of the isolated colon, and the oral and anal 
ends were tied securely to the respective tubes, K-H solution was 
pumped (0.25 mL/min) into the lumen of the preparation using a 
peristaltic pump (Masterflex 7523-30 with cartridge 3519-85; 
Cole-Palmer, Chicago, IL, USA) to induce peristalsis. The time 
it took the pellet to shift a distance of 2 cm was measured. Colonic 
transit time was assessed as the mean of pellet transit times 
through each of 4 consecutive colonic segments. The time re-
quired to move the first 2-cm distance was excluded from the 
analysis. After perfusion of control solution for periods of 60 mi-
nutes, the SKI3246 (50, 75, and 100 mg/mL) was applied to the 
bathing solution.
Effect of SKI3246 on upper gastrointestinal conditions 
induced by thyrotropin-releasing hormone or mustard oil 
GI transit was measured using the charcoal transit assay. The 
charcoal mixture consisted of charcoal, barium and normal saline 
in a 1:2:6 mixture. The guinea pigs were fasted for more than 8 
hours before the experiment. The TRH (100 g/kg) was in-
jected subcutaneously, and MO (10 mg/kg) was administered 
orally. After 30 minutes, SKI3246 (150, 300, and 600 mg/kg) 
was administered using an orogastric cannula. For the assay in 
the naive condition, SKI3246 was administered to the guinea pigs 
without pretreatment. After another 30 minutes, the guinea pigs 
received the charcoal mixture by intragastric administration. 
Upper GI transit was evaluated as the distance (cm) from the py-
lorus to the most distal point of migration of the charcoal mixture 
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Figure 1. Effect of SKI3246 on colonic transit time in isolated colonic 
segments from guinea pigs (n = 5). The colonic transit time was 
significantly increased at higher concentrations of SKI3246 compared 
with the control group (75 g/mL and 100 g/mL, both groups P = 
0.043) and the effect was dose-dependent (Wilcoxon signed rank test).
and expressed as a percentage (%) of the total distance traveled by 
the charcoal mix through the length of the small intestine (cm). 
The distance moved through the small intestine represents both 
gastric transit and small bowel transit. In this context, small intes-
tine transit is used interchangeably with upper GI transit.6 
Effect of SKI3246 on normal lower gastrointestinal 
motility and on motility following treatment with 
thyrotropin-releasing hormone or mustard oil 
In the fecal pellet output assay, TRH (100 g/kg) was in-
jected subcutaneously or MO (10 mg/kg) was administered 
through an orogastric cannula. After 30 minutes, SKI3246 (150, 
300, and 600 mg/kg) was administered through the cannula. 
SKI3246 (150, 300, and 600 mg/kg) was also administered to a 
group of guinea pigs without pretreatment. Each guinea pig was 
placed into an individual experimental cage, and both the weight 
and number of fecal pellets produced were measured and re-
corded at 1-hour intervals for the first 4 hours. As a result, a 
4-hour cumulative fecal pellet output was measured for each 
guinea pig. 
Statistical Methods
Non-parametric methods were used in all statistical analyses, 
since the number of experimental subjects per group was less than 
10. The Wilcoxon signed rank test was used to analyze colonic 
transit time and the Mann-Whitney test was used in the upper GI 
transit analysis. Results of the fecal expulsion study were analyzed 
by the repeated measures ANOVA. If the spherocity assumption 
was not fulfilled on Mauchly’s test, then the Greenhouse-Geisser 
correction method was used. Statistical significance was de-
termined at the 5% level. All data were analyzed using SPSS ver-
sion 18.0 (SPSS Inc, Chicago, IL, USA).
Results
Effect of SKI3246 on Colonic Transit Time 
In comparison to control treatment, SKI3246 at the lowest 
concentration used (50 g/mL), had no effect on colonic transit 
time. However, the mean colonic transit time was significantly in-
creased at higher SKI3246 concentrations (2.8 times at 75 
g/mL and 11.4 times at 100 g/mL, both groups P = 0.043), 
and the effect showed a dose-dependent tendency (Fig. 1).
Effects of SKI3246 on Normal Upper 
Gastrointestinal Transit and on Transit 
Conditions Induced by Thyrotropin-releasing 
Hormone or Mustard Oil 
In guinea pigs receiving no pretreatment, SKI3246 had no 
effect on charcoal transit compared with the control group (150, 
300, and 600 mg/kg, respectively) (Fig. 2A). 
In comparison to the control group, the groups treated with 
TRH (100 g/kg) showed no difference in charcoal transit (Fig. 
2B). Moreover, SKI3246 had no effect on charcoal transit at any 
of 3 dose levels compared with control groups (150, 300, and 600 
mg/kg, respectively) among TRH-pretreated groups. 
In comparison to the control groups, groups treated with 
MO (10 mg/kg) displayed significantly elongated charcoal transit 
(% of charcoal migration: 58.40 ± 10.84 vs 88.32 ± 15.26, re-
spectively; P = 0.009) (Fig. 2C). Among MO-pretreated 
groups, SKI3246 had no effect on charcoal transit at lower doses 
(150 mg/kg and 300 mg/kg). At a higher dose (600 mg/kg), 
however, SKI3246 significantly shortened the charcoal transit (% 
of charcoal migraion: 88.32 ± 15.26 vs 60.82 ± 15.62, re-
spectively; P = 0.030)  (Fig. 2C).
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Figure 2. Effect of SKI3246 on upper gastrointestinal (GI) transit time of guinea pigs. (A) Effect of SKI3246 on upper GI transit time of guinea pigs
in the native condition (n = 6). SKI3246 had no effect on charcoal transit time at 3 dose levels as compared with the control group by Mann-Whitney 
test. (B) Effect of SKI3246 on upper GI transit time in TRH-pretreated guinea pigs (control groups, n = 6; TRH pretreatment control groups, n = 
5; SKI3246 treated groups, n = 7). Guinea pigs pretreated with TRH (100 g/kg) showed no difference in charcoal transit compared with the control
group. As compared with the control group, SKI3246 showed no effect on charcoal transit at 3 different dose levels among groups pretreated with 
TRH. (C) Effect of SKI3246 on upper GI transit in mustard oil (MO)-pretreated guinea pigs (control groups, n = 6; MO pretreatment control 
groups, n = 5; SKI3246 treated groups, n = 7). Groups pretreated with MO (10 mg/kg) displayed significantly elongated charcoal transit compared 
with the control group (P = 0.009). Among MO-pretreated groups, SKI3246 had no effect on charcoal transit at lower doses compared with control 
group. At a higher dose (600 mg/kg), however, SKI3246 significantly shortened the charcoal transit (P = 0.030). The error bars indicate standard 
deviation. 
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Figure 3. Effect of SKI3246 on lower gastrointestinal motility in the native guinea pigs. (A) Effect of SKI3246 on the cumulative number of egested 
pellets in guinea pigs in the native condition (control group, n = 7; treatment groups, n = 6). The cumulative number of egested pellets did not differ 
among the four groups, including a control group and groups treated with SKI3246 at 150, 300, and 600 mg/kg by the repeated measures ANOVA 
test or Greenhouse-Geisser correction method. There was no group effect (F = 0.054, P = 0.983), whereas time effect was present (F = 42.87, P ＜
0.001). (B) Effect of SKI3246 on cumulative weight of egested pellets in guinea pigs in the native condition (control group, n = 7; treatment groups, 
n = 6). The cumulative weight of egested pellets did not differ among the four groups, including a control group and groups treated with SKI3246 
at 150, 300, and 600 mg/kg by the repeated measures ANOVA test or Greenhouse-Geisser correction method. There was no group effect (F = 0.235, 
P = 0.639), whereas time effect was present (F = 30.41, P ＜ 0.001). The error bars indicate standard deviation.
Effect of SKI3246 on Lower Gastrointestinal 
Motility in the Native Condition and 
Conditions Induced by Thyrotropin-releasing 
Hormone or Mustard Oil 
In the fecal expulsion test of guinea pigs in the native con-
dition, cumulative number and weight of egested pellets did not 
differ among 4 groups, including the control group and groups 
treated with SKI3246 at 3 dose levels (150, 300, and 600 mg/kg) 
(Fig. 3). 
Cumulative number and weight of egested pellets did not dif-
fer between the control group and groups pretreated with TRH 
(100 g/kg) (Fig. 4). In the fecal expulsion test of guinea pigs 
pretreated with TRH, cumulative number and weight of egested 
pellets did not differ between the control group and groups treat-
ed with low dose SKI3246 (150 mg/kg) (Fig. 4). However, the 
cumulative number and weight of egested pellets were sig-
nificantly higher in groups that received higher doses of SKI3246 
compared with the control group (P = 0.015 and P = 0.006, re-
spectively at 300 mg/kg; P = 0.040 and P = 0.023, respectively 
at 600 mg/kg) (Fig. 4). 
Cumulative number and weight of egested pellets were sig-
nificantly higher in MO-treated groups than in control groups 
(P = 0.001 and P = 0.013, respectively; Fig. 5). Among groups 
pretreated with MO, cumulative number and weight of egested 
pellets did not differ between the control group and groups pre-
treated with MO at three different doses of SKI3246 (Fig. 5). 
Discussion
In this study, we demonstrated that the extract of A. japonica 
rhizome, SKI3246, had no significant effect on the upper GI 
tract in the guinea pig either before or after exposure to TRH and 
MO. In the in vitro system, however, the extract induced an in-
crease in colonic transit time, and in the in vivo study, SKI3246 
affected lower GI tract activity, significantly decreasing the weight 
and number of fecal pellets following treatment with TRH. 
Two models of altered gut functions were used for this study, 
one based on the action of TRH and the other on the irritant 
properties of mustard oil. MO, allyl isothiocyanate, the predom-
inant aromatic constituent of mustard, horseradish, and wasabi, is 
a direct stimulant of small nerve fibers and a potent acute in-
flammatory irritant.7 Although the GI response to MO in guinea 
pig is not well-documented, the intra-colonic administration of 
MO in mice results in acute colitis, which may progress to an 
IBS-like acceleration of upper GI transit.7 In our guinea pig 
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Figure 4. Effect of SKI3246 on lower gastrointestinal motility in thyrotropin-releasing hormone (TRH) pretreated guinea pigs. (A) Effect of 
SKI3246 on the cumulative number of egested pellets in guinea pigs pretreated with TRH (control group, n = 7; treatment groups, n = 6). Among 
TRH-pretreated animals, the cumulative number of egested pellets did not differ between the control group and the group treated with the lowest dose 
of SKI3246 (150 mg/kg). However, the cumulative number of egested pellets in the groups that received higher doses of SKI3246 was significantly 
higher than that of the control group (300 mg/kg, P = 0.015 and 600 mg/kg, P = 0.040) by the repeated measures ANOVA test or 
Greenhouse-Geisser correction method. The group and time differences between subgroups are as follows: (1) Control vs TRH: group and time effect 
(F = 1.33, P = 0.274 and F = 27.59, P ＜ 0.001), (2) TRH vs TRH + SKI3246 150 mg: group and time effect (F = 1.10, P = 0.319 and F = 
15.24, P = 0.001), (3) TRH vs TRH + SKI3246 300 mg: group and time effect (F = 6.17, P = 0.032 and F = 21.96, P ＜ 0.001), (4) TRH vs 
TRH + SKI3246 600mg: Group and time effect (F=4.27, P=0.066 and F=24.67, P ＜ 0.001), (5) TRH + SKI3246 150 mg vs TRH + SKI3246 
300 mg: group and time effect (F = 3.87, P = 0.077 and F = 6.43, P = 0.002), (6) TRH + SKI3246 150 mg vs TRH + SKI3246 600 mg: group 
and time effect (F = 1.75, P = 0.215 and F = 7.66, P = 0.011), (7) TRH + SKI3246 300 mg vs TRH + SKI3246 600 mg: group and time effect 
(F = 1.17, P = 0.305 and F = 11.75, P = 0.002). (B) Effect of SKI3246 on the cumulative weight of egested pellets in guinea pigs pretreated with 
TRH (control group, n = 7; treatment groups, n = 6). Among TRH-pretreated groups, the cumulative weight of egested pellets did not differ 
between the control group and the group given the lowest dose of SKI3246 (150 mg/kg). However, as compared to control values, the cumulative 
weight of egested pellets was significantly higher in groups that received SKI3246 at higher doses (300 mg/kg, P = 0.006; and 600 mg/kg, P = 0.023) 
by the repeated measures ANOVA test or Greenhouse-Geisser correction method. The group and time differences between subgroups are as follows: 
(1) Control vs TRH: group and time effect (F = 0.78, P = 0.397 and F = 27.80, P ＜ 0.001), (2) TRH vs TRH + SKI3246 150 mg: group and 
time effect (F = 1.56, P = 0.240 and F = 18.12, P ＜ 0.001), (3) TRH vs TRH + SKI3246 300 mg: group and time effect (F = 5.82, P = 0.037 
and F = 22.71, P ＜ 0.001), (4) TRH vs TRH + SKI3246 600 mg: group and time effect (F = 4.30, P = 0.065 and F = 24.37, P ＜ 0.001), (5) 
TRH + SKI3246 150 mg vs TRH + SKI3246 300 mg: group and time effect (F = 4.15, P = 0.069 and F = 7.86, P = 0.007), (6) TRH + SKI3246 
150 mg vs TRH + SKI3246 600 mg: group and time effect (F = 1.86, P = 0.203 and F = 9.13, P ＜ 0.001), (7) TRH + SKI3246 300 mg vs TRH 
+ SKI3246 600 mg: group and time effect (F= 0.847, P = 0.379 and F=14.15, P < 0.001). The error bars indicate standard deviation.
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Figure 5. Effect of SKI3246 on lower gastrointestinal motility in mustard oil (MO) pretreated guinea pigs. (A) Effect of SKI3246 on the cumulative 
number of egested pellets in guinea pigs pretreated with MO (control group, n = 7; treatment groups, n = 6). The cumulative number of egested 
pellets was significantly higher in the MO-pretreated groups than in the control group (P = 0.001). Among groups pretreated with MO, the 
cumulative number of egested pellets did not differ from the control value or from MO-pretreated groups given any dose of SKI3246 (P = 0.705, P
= 0.451, and P = 683, at 150, 300, and 600 mg/kg, respectively, using repeated measures ANOVA test or Greenhouse-Geisser correction method). 
The group and time differences between subgroups are as follows: (1) Control vs MO: group and time effect (F = 0.65, P = 0.436 and F = 31.70, 
P ＜ 0.001), (2) MO vs MO + SKI3246 150 mg: group and time effect (F = 0.39, P = 0.545 and F = 50.34, P ＜ 0.001), (3) MO vs MO + 
SKI3246 300 mg: group and time effect (F = 0.38, P = 0.551 and F = 38.93, P ＜ 0.001), (4) MO vs MO + SKI3246 600 mg: group and time 
effect (F = 0.10, P = 0.761 and F = 41.94, P ＜ 0.001), (5) MO + SKI3246 150 mg vs MO + SKI3246 300 mg: group and time effect (F = 1.68, 
P = 0.224 and F = 40.50, P ＜ 0.001), (6) MO + SKI3246 150 mg vs MO + SKI3246 600 mg: group and time effect (F = 1.25, P = 0.290 and 
F = 44.69, P ＜ 0.001), (7) MO + SKI3246 300 mg vs MO + SKI3246 600 mg: group and time effect (F = 0.13, P = 0.729 and F = 35.98, P
＜ 0.001). (B) Effect of SKI3246 on the cumulative weight of egested pellets in guinea pigs pretreated with MO (control group, n = 7; treatment 
groups, n = 6). The cumulative weight of egested pellets was significantly higher in the MO-pretreated groups than in the control group (P = 0.013).
Among groups pretreated with MO, the cumulative weight of egested pellets did not differ significantly from control values and from values for groups
receiving any dose of SKI3246 by the repeated measures ANOVA or Greenhouse-Geisser correction method. The group and time differences between 
subgroups are as follows: (1) Control vs MO: group and time effect (F = 0.26, P = 0.623 and F = 25.94, P ＜ 0.001), (2) MO vs MO + SKI3246 
150 mg: group and time effect (F = 0.12, P = 0.740 and F = 42.81, P ＜ 0.001), (3) MO vs MO + SKI3246 300 mg: group and time effect (F 
= 0.06, P = 0.817 and F = 34.01, P ＜ 0.001), (4) MO vs MO + SKI3246 600 mg: group and time effect (F = 0.04, P = 0.849 and F = 32.30, 
P ＜ 0.001), (5) MO + SKI3246 150 mg vs MO + SKI3246 300 mg: group and time effect (F = 0.02, P = 0.895 and F = 60.93, P ＜ 0.001), 
(6) MO + SKI3246 150 mg vs MO + SKI3246 600 mg: group and time effect (F = 0.04, P = 0.839 and F = 46.29, P ＜ 0.001), (7) MO + 
SKI3246 300 mg vs MO + SKI3246 600 mg: group and time effect (F = 0.01, P = 0.950 and F = 35.97, P ＜ 0.001). The error bars indicate 
standard deviation.
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model, MO, significant elongated upper GI transit and increased 
the number and weight of fecal pellets. On the whole, SKI3246 
did not affect either upper or lower GI transit in the MO-in-
duced model, although at the highest dose it slowed upper GI 
transit. Although the pharmacological action of SKI3246 is not 
completely defined, this complex preparation has been shown its 
action through the neurokinin (NK) receptor antagonism, espe-
cially NK2 receptor.1 Meanwhile, it has been known that MO 
displays proinflammatory activity mainly via inducing plasma ex-
travasation, which is principally due to the release of substance P 
and to NK1 receptor activation.7-10 These differences in mecha-
nism between the 2 agents may explain in part the lack of GI mo-
tility response to SKI3246 in the MO-induced model in this 
study. 
In the in vitro experiments, SKI3246 significantly increased 
colonic transit time, in contrast to its effect in the intact guinea 
pig. As measured by the fecal expulsion test, SKI3246 did not af-
fect GI motility in vivo at any dose level applied. These somewhat 
discrepant results might be due to physiologic counterbalance 
mechanism in in vivo condition, that might be impaired in in vi-
tro isolated colonic segment unit. Moreover, although the control 
of intrinsic nervous system and smooth muscle response to the 
exogenous drug challenge are intact, control of extrinsic nervous 
system and GI hormonal regulation may be lacking in in vitro 
conditions. 
TRH, an agent of the hypothalamic-pituitary axis, partic-
ipates in central regulation of peripheral autonomic function. 
Administered centrally or peripherally, TRH may influence GI 
motility. Centrally administered TRH stimulates gastric motility 
in rats,11 small intestinal transit in rats,12 and colonic activity in 
rabbits.13 Administered intravenously, TRH stimulates gastric 
action potentials in dogs;14 and subcutaneously injected TRH 
may increase fecal pellet output in rats.15 The GI response to 
TRH administered subcutaneously in the guinea pig has not 
been studied in detail; however, one in vitro study showed that 
TRH stimulates motility of the gastric antrum, small intestine 
and taenia coli of the guinea pig.16 In our study, TRH increased 
upper GI transit and the number and weight of fecal pellet ex-
pulsion, although the effect did not reach statistical significance. 
In the altered guinea pig model induced by TRH, SKI3246 sig-
nificantly decreased number and weight of fecal pellets at 300 
mg/kg and 600 mg/kg doses; however, it did not affect upper GI 
transit in this model. With respect to the mechanism by which 
TRH may affect bowel function, it is reported that TRH acts 
centrally to induce cholinergic and serotonergic vagal stimulation 
of GI secretory and motor function.15 The effect of TRH also de-
pends on endogenous 5-hydroxytryptamine (serotonin or 5-HT) 
release from the enterocromaffin cell and/or enteric serotonergic 
neurons in the intestine. Thus, the effect of SKI3246 on GI mo-
tility may also plausibly be related to blockade of cholinergic or 
serotonergic response, apart from the NK2 pathway. 
In the in vitro assay, SKI3246 increased colonic transit time 
with a dose-dependent tendency. In contrast, its effect on fecal 
expulsion in the intact animal was not a dose-dependent manner, 
showing no difference between SKI3246 treatments at 300 mg/kg 
and 600 mg/kg. This finding implies that at least the dose of 300 
mg/kg might be needed for substantial effect on altered lower GI 
condition by TRH. With respect to upper GI motility in the 
guinea pig, SKI3246 showed no effect in either the native or 
TRH-induced condition. At a high dose (600 mg/kg), however, 
SKI3246 inhibited transit in the upper GI tract pretreated by 
MO. These findings suggest that optimal dose determination will 
be an important consideration in future clinical trials of SKI3246, 
since our data imply that upper gastrointestinal side effects of 
SKI3246, including nausea or vomiting can occur at higher doses. 
The condition induced by TRH in the guinea pig resembles 
conditions observed clinically, such as diarrhea or IBS with diar-
rhea, and SKI3246 significantly decreased bowel movement 
which was measured by the weight and number of fecal pellets. In 
addition to the effect on bowel motility, SKI3246 significantly re-
duces visceral pain in rats.1 The capability of SKI3246 to influ-
ence both bowel movement and visceral pain supports further in-
vestigation of SKI3246 as a treatment for IBS with diarrhea pre-
senting with both pain and diarrhea. 
In conclusion, the extract of A. japonica rhizome SKI3246 
showed no significant effect on upper GI tract motility in guinea 
pigs, in either the native or altered conditions induced by MO or 
TRH. In the in vitro model, however, SKI3246 significantly in-
creased colonic transit time. Effects of SKI3246 in vivo were 
largely confined to the lower GI tract, significantly decreasing the 
weight and number of fecal pellets in animals with induced 
diarrhea. These findings justify further investigation of SKI3246 
for use in treating IBS with diarrhea as a prominent component. 
Moreover, further investigation of the pharmacologic action of 
SKI3246 on GI motility is also warranted. 
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